Women's Health Diagnostics Market by Type, Application, End-User

Description

List of Tables

The Global Women's Health Diagnostics Market is forecasted to grow significantly, with a projected USD 43.95 billion in 2023 at a CAGR of 9.08% and expected to reach a staggering USD 80.91 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Women's Health Diagnostics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Women's Health Diagnostics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Point-of-Care and Self Check. The Point-of-Care is projected to witness significant market share during forecast period.

Based on Application, market is studied across Breast Cancer Testing, Cervical Cancer Testing, Infectious Disease Testing, Osteoporosis Testing, Ovarian Cancer Testing, Pregnancy & Fertility Testing, Prenatal Genetic Screening & Carrier Testing, Sexually Transmitted Disease Testing, and Ultrasound Tests. The Breast Cancer Testing is further studied across Biopsies, Blood Chemistries & Blood Cell Count Tests, Breast Cancer Tumor Marker Tests, and Mammography. The Cervical Cancer Testing is further studied across HPV Testing and PAP Smear. The Infectious Disease Testing is further studied across HEPAtitis Testing, MRSA Testing, Tuberculosis Testing, and Urinary Tract Infection Testing (Vaginal pH & Vaginitis). The Osteoporosis Testing is further studied across Bone Densitometry and in Vitro Blood Tests. The Ovarian Cancer Testing is further studied across Diagnostic Imaging Tests and Ovarian Cancer Tumor Marker Tests. The Pregnancy & Fertility Testing is further studied across Fertility Monitors, Lab-Based Testing, and Pregnancy Testing & Ovulation Prediction Kits. The Prenatal Genetic Screening & Carrier Testing is further studied across Cystic Fibrosis, Down Syndrome & Edwards Syndrome, and Torch Infections. The Sexually Transmitted Disease Testing is further studied across Chlamydia Trachomatis & Neisseria Gonorrhoeae (CT/NG) Testing and HIV Testing. The Ultrasound Tests is further studied across Breast Imaging and OB/GYN Imaging. The Osteoporosis Testing is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Diagnostic & Imaging Centers, Home Care, and Hospitals & Clinics. The Hospitals & Clinics is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Women's Health Diagnostics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Women's Health Diagnostics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Women's Health Diagnostics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Women's Health Diagnostics Market?

4. What is the competitive strategic window for opportunities in the Global Women's Health Diagnostics Market?

5. What are the technology trends and regulatory frameworks in the Global Women's Health Diagnostics Market?

6. What is the market share of the leading vendors in the Global Women's Health Diagnostics Market?

7. What modes and strategic moves are considered suitable for entering the Global Women's Health Diagnostics Market?

Product Code: MRR-43477954269D

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Women's Health Diagnostics Market, by Type, 2022 vs 2030
4.3. Women's Health Diagnostics Market, by Application, 2022 vs 2030
4.4. Women's Health Diagnostics Market, by End-User, 2022 vs 2030
4.5. Women's Health Diagnostics Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing instances of chronic and life style- related disorders in women
  - 5.1.1.2. Adoption of point-of-care and rapid diagnostic tests
  - 5.1.1.3. Availability of imaging and private diagnostic centres
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with procedures and diagnostic imaging system
- 5.1.3. Opportunities
  - 5.1.3.1. Improved and technically advanced healthcare infrastructure
  - 5.1.3.2. Growing focus on microfluidics and nanotechnology-based POC devices for diagnostic
  - 5.1.3.3. Clinical trial assessment for the diagnosis of several cancer's associated with the women
- 5.1.4. Challenges
  - 5.1.4.1. Limited technically skilled lab assistants
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Women's Health Diagnostics Market, by Type

6.1. Introduction
6.2. Point-of-Care
6.3. Self Check

7. Women's Health Diagnostics Market, by Application

7.1. Introduction
7.2. Breast Cancer Testing
- 7.2.1. Biopsies
- 7.2.2. Blood Chemistries & Blood Cell Count Tests
- 7.2.3. Breast Cancer Tumor Marker Tests
- 7.2.4. Mammography
7.3. Cervical Cancer Testing
- 7.3.1. HPV Testing
- 7.3.2. PAP Smear
7.4. Infectious Disease Testing
- 7.4.1. HEPAtitis Testing
- 7.4.2. MRSA Testing
- 7.4.3. Tuberculosis Testing
- 7.4.4. Urinary Tract Infection Testing (Vaginal pH & Vaginitis)
7.5. Osteoporosis Testing
- 7.5.1. Bone Densitometry
- 7.5.2. in Vitro Blood Tests
7.6. Ovarian Cancer Testing
- 7.6.1. Diagnostic Imaging Tests
- 7.6.2. Ovarian Cancer Tumor Marker Tests
7.7. Pregnancy & Fertility Testing
- 7.7.1. Fertility Monitors
- 7.7.2. Lab-Based Testing
- 7.7.3. Pregnancy Testing & Ovulation Prediction Kits
7.8. Prenatal Genetic Screening & Carrier Testing
- 7.8.1. Cystic Fibrosis
- 7.8.2. Down Syndrome & Edwards Syndrome
- 7.8.3. Torch Infections
7.9. Sexually Transmitted Disease Testing
- 7.9.1. Chlamydia Trachomatis & Neisseria Gonorrhoeae (CT/NG) Testing
- 7.9.2. HIV Testing
7.10. Ultrasound Tests
- 7.10.1. Breast Imaging
- 7.10.2. OB/GYN Imaging

8. Women's Health Diagnostics Market, by End-User

8.1. Introduction
8.2. Diagnostic & Imaging Centers
8.3. Home Care
8.4. Hospitals & Clinics

9. Americas Women's Health Diagnostics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Women's Health Diagnostics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Women's Health Diagnostics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

1. Abbott Laboratories

2. AccuBioTech Co., Ltd.

3. Alere Inc.

4. Becton, Dickinson and Company

5. Biomerieux SA

6. Cardinal Health, Inc.

7. Carestream Health, Inc.

8. Chembio Diagnostic Systems, Inc.

9. Cook Medical, Inc.

10. Danaher Corporation

11. DIALAB GmbH

12. EKF Diagnostics Holdings plc

13. F. Hoffmann-La Roche Ltd.

14. FUJIFILM Holdings Corporation

15. GE Healthcare

16. Guided Therapeutics, Inc.

17. Hologic, Inc.

18. Koninklijke Philips N.V.

19. MedGyn Products, Inc.

20. NeuroLogica Corporation

21. Nova Biomedical

22. Osteometer MediTech, Inc.

23. Perkinelmer Inc.

24. Quest Diagnostics Incorporated

25. Siemens AG

26. SuperSonic Imagine

27. WerfenLife, S.A.